Yehuda Carmeli

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi Antecedent treatment with different antibiotic agents as a risk factor for vancomycin-resistant Enterococcus
    Yehuda Carmeli
    Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    Emerg Infect Dis 8:802-7. 2002
  2. ncbi Use of insurance claims data to assess outpatient antimicrobial therapy for gram-positive infections
    Yehuda Carmeli
    Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215, USA
    Pharmacotherapy 22:55S-62S. 2002
  3. ncbi Health and economic outcomes of vancomycin-resistant enterococci
    Yehuda Carmeli
    Division of Infectious Diseases, Tel Aviv Sourasky Medical Center, 6 Weizman St, Tel Aviv 62749, Israel
    Arch Intern Med 162:2223-8. 2002
  4. ncbi Transfer of carbapenem-resistant plasmid from Klebsiella pneumoniae ST258 to Escherichia coli in patient
    Moran G Goren
    Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
    Emerg Infect Dis 16:1014-7. 2010
  5. ncbi Isolation of imipenem-resistant Enterobacter species: emergence of KPC-2 carbapenemase, molecular characterization, epidemiology, and outcomes
    Dror Marchaim
    Division of Epidemiology, Tel Aviv Sourasky Medical Center, 6 Weizmann St, Tel Aviv 64239, Israel
    Antimicrob Agents Chemother 52:1413-8. 2008
  6. ncbi Cost-effectiveness evaluation of ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections accounting for antibiotic resistance
    Jeroen P Jansen
    Mapi Values, Boston, MA 02108, USA
    Value Health 12:234-44. 2009
  7. ncbi Evaluation of PCR-based testing for surveillance of KPC-producing carbapenem-resistant members of the Enterobacteriaceae family
    Vered Schechner
    Division of Epidemiology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
    J Clin Microbiol 47:3261-5. 2009
  8. ncbi Predictors of carbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition on mortality
    Mitchell J Schwaber
    Division of Epidemiology and Preventive Medicine, Tel Aviv Sourasky Medical Center, 6 Weizmann St, Tel Aviv 64239, Israel
    Antimicrob Agents Chemother 52:1028-33. 2008
  9. ncbi Emergence of KPC-2 and KPC-3 in carbapenem-resistant Klebsiella pneumoniae strains in an Israeli hospital
    Azita Leavitt
    Division of Epidemiology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
    Antimicrob Agents Chemother 51:3026-9. 2007
  10. ncbi Ertapenem resistance among extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae isolates
    Azita Leavitt
    Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
    J Clin Microbiol 47:969-74. 2009

Detail Information

Publications88

  1. ncbi Antecedent treatment with different antibiotic agents as a risk factor for vancomycin-resistant Enterococcus
    Yehuda Carmeli
    Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    Emerg Infect Dis 8:802-7. 2002
    ..Vancomycin was not a risk factor for isolation of VRE...
  2. ncbi Use of insurance claims data to assess outpatient antimicrobial therapy for gram-positive infections
    Yehuda Carmeli
    Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215, USA
    Pharmacotherapy 22:55S-62S. 2002
    ..To demonstrate this approach, a study of the cost of intravenous vancomycin home care therapy was conducted using claims data from a large insurance company...
  3. ncbi Health and economic outcomes of vancomycin-resistant enterococci
    Yehuda Carmeli
    Division of Infectious Diseases, Tel Aviv Sourasky Medical Center, 6 Weizman St, Tel Aviv 62749, Israel
    Arch Intern Med 162:2223-8. 2002
    ..The health and economic impact of vancomycin-resistant enterococci has not been quantified...
  4. ncbi Transfer of carbapenem-resistant plasmid from Klebsiella pneumoniae ST258 to Escherichia coli in patient
    Moran G Goren
    Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
    Emerg Infect Dis 16:1014-7. 2010
    ..The KPC-3 plasmid was identical in isolates of both species. The patient's gut flora contained a carbapenem-susceptible E. coli strain isogenic with the KPC-3-producing isolate, which suggests horizontal interspecies plasmid transfer...
  5. ncbi Isolation of imipenem-resistant Enterobacter species: emergence of KPC-2 carbapenemase, molecular characterization, epidemiology, and outcomes
    Dror Marchaim
    Division of Epidemiology, Tel Aviv Sourasky Medical Center, 6 Weizmann St, Tel Aviv 64239, Israel
    Antimicrob Agents Chemother 52:1413-8. 2008
    ..IRE infections are associated with increased mortality. Enhanced measures to control the hospital spread of IRE are warranted...
  6. ncbi Cost-effectiveness evaluation of ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections accounting for antibiotic resistance
    Jeroen P Jansen
    Mapi Values, Boston, MA 02108, USA
    Value Health 12:234-44. 2009
    ..To evaluate the cost-effectiveness of ertapenem versus piperacillin/tazobactam in the treatment of community-acquired complicated intraabdominal infections accounting for development of antibiotic resistance in the Dutch setting...
  7. ncbi Evaluation of PCR-based testing for surveillance of KPC-producing carbapenem-resistant members of the Enterobacteriaceae family
    Vered Schechner
    Division of Epidemiology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
    J Clin Microbiol 47:3261-5. 2009
    ..blaKPC PCR-based testing is a useful method for the surveillance of KPC-producing CRE. Its main advantage over culturing is a shorter time to result, and it may prove to be more sensitive...
  8. ncbi Predictors of carbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition on mortality
    Mitchell J Schwaber
    Division of Epidemiology and Preventive Medicine, Tel Aviv Sourasky Medical Center, 6 Weizmann St, Tel Aviv 64239, Israel
    Antimicrob Agents Chemother 52:1028-33. 2008
    ..6; and P = 0.03; for the CRKP group versus the controls, OR, 5.0; 95% CI, 1.7 to 14.8; and P = 0.004). CRKP affects patients with poor functional status, an ICU stay, and antibiotic exposure and is an independent predictor of death...
  9. ncbi Emergence of KPC-2 and KPC-3 in carbapenem-resistant Klebsiella pneumoniae strains in an Israeli hospital
    Azita Leavitt
    Division of Epidemiology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
    Antimicrob Agents Chemother 51:3026-9. 2007
    ..This rapid dissemination of KPC outside the United States is worrisome...
  10. ncbi Ertapenem resistance among extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae isolates
    Azita Leavitt
    Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
    J Clin Microbiol 47:969-74. 2009
    ..These rare resistant subpopulations carried multiple ESBL genes, including TEM-30, SHV-44, CTX-M-2, and CTX-M-10, and they lacked OMPK36. The clinical and diagnostic significance of the results should be further studied...
  11. ncbi Treatment with fluoroquinolones or with beta-lactam-beta-lactamase inhibitor combinations is a risk factor for isolation of extended-spectrum-beta-lactamase-producing Klebsiella species in hospitalized patients
    Kenneth M Wener
    Department of Infectious Diseases, Lahey Clinic, Burlington, Massachusetts, USA
    Antimicrob Agents Chemother 54:2010-6. 2010
    ..Formulary interventions to limit the spread of ESBL-producing isolates should be tailored to each setting...
  12. ncbi First report on a hyperepidemic clone of KPC-3-producing Klebsiella pneumoniae in Israel genetically related to a strain causing outbreaks in the United States
    Shiri Navon-Venezia
    Division of Epidemiology, Tel Aviv Sourasky Medical Center, Israel
    Antimicrob Agents Chemother 53:818-20. 2009
    ..The threat of the global spread of hyperepidemic, extensively drug-resistant bacterial strains should be recognized and confronted...
  13. ncbi Dissemination of the CTX-M-25 family beta-lactamases among Klebsiella pneumoniae, Escherichia coli and Enterobacter cloacae and identification of the novel enzyme CTX-M-41 in Proteus mirabilis in Israel
    Shiri Navon-Venezia
    Division of Epidemiology, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
    J Antimicrob Chemother 62:289-95. 2008
    ..We aimed to describe the occurrence and to understand the dissemination of this extended-spectrum beta-lactamase family among Enterobacteriaceae strains in our hospital...
  14. ncbi Pseudomonas aeruginosa bacteremia upon hospital admission: risk factors for mortality and influence of inadequate empirical antimicrobial therapy
    Vered Schechner
    Division of Epidemiology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
    Diagn Microbiol Infect Dis 71:38-45. 2011
    ..029) were identified as independent predictors of mortality. Inadequate empirical antimicrobial therapy was marginally associated with increased mortality only among patients who presented with severe sepsis or septic shock (P = 0.051)...
  15. ncbi Clinical and economic impact of bacteremia with extended- spectrum-beta-lactamase-producing Enterobacteriaceae
    Mitchell J Schwaber
    Division of Epidemiology, Tel Aviv Sourasky Medical Center, 6 Weizmann St, Tel Aviv 64239, Israel
    Antimicrob Agents Chemother 50:1257-62. 2006
    ..ESBL production was associated with severe adverse outcomes, including higher overall and infection-related mortality, increased LOS, DAT, discharge to chronic care, and higher costs...
  16. ncbi Risk factors for albicans and non-albicans candidemia in the intensive care unit
    Jennifer K Chow
    Division of Geographic Medicine and Infectious Diseases, Tufts New England Medical Center, Tufts University School of Medicine, Boston, MA, USA
    Crit Care Med 36:1993-8. 2008
    ..To determine risk factors for bloodstream infections (BSI) with Candida non-albicans (C-NA) species and Candida albicans (CA) among critically ill patients...
  17. ncbi Molecular and epidemiologic study of polyclonal outbreaks of multidrug-resistant Acinetobacter baumannii infection in an Israeli hospital
    Dror Marchaim
    Division of Epidemiology, Tel Aviv Sourasky Medical Center, Sackler School of Medicine, Tel Aviv University, Tel Aviv, 64239, Israel
    Infect Control Hosp Epidemiol 28:945-50. 2007
    ....
  18. ncbi The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges
    Sara E Cosgrove
    Division of Infectious Diseases, Johns Hopkins Medical Institutions, The Johns Hopkins Hospital, Baltimore, Maryland 21287, USA
    Infect Control Hosp Epidemiol 26:166-74. 2005
    ..To evaluate the impact of methicillin resistance in Staphylococcus aureus on mortality, length of hospitalization, and hospital charges...
  19. ncbi Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008
    Moran G Goren
    The Molecular Epidemiology and Antibiotic Resistance Laboratory, Division of Epidemiology, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
    Antimicrob Agents Chemother 54:2687-91. 2010
    ..Tn4401 elements were identified in all of these plasmids...
  20. ncbi Clinical implications of varying degrees of vancomycin susceptibility in methicillin-resistant Staphylococcus aureus bacteremia
    Mitchell J Schwaber
    Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    Emerg Infect Dis 9:657-64. 2003
    ..These data show that patients with vancomycin-susceptible MRSA bacteremia have similar baseline clinical features and outcomes whether or not their bacterial isolates exhibit growth on screening media containing vancomycin...
  21. ncbi Plasmid-mediated imipenem-hydrolyzing enzyme KPC-2 among multiple carbapenem-resistant Escherichia coli clones in Israel
    Shiri Navon-Venezia
    Division of Epidemiology, Tel Aviv Sourasky Medical Center, Tel Aviv University, Israel
    Antimicrob Agents Chemother 50:3098-101. 2006
    ..This is the first discovery of KPC-2 in E. coli and the first report of this enzyme originating outside the United States...
  22. ncbi Efficacy of antibodies against the N-terminal of Pseudomonas aeruginosa flagellin for treating infections in a murine burn wound model
    Yoav Barnea
    Department of Plastic and Reconstructive Surgery, Division of Epidemiology and Laboratory for Molecular Epidemiology and Antimicrobials Research, Pathology Institute, Tel Aviv Sourasky Medical Center, Tel Aviv 64239, Israel
    Plast Reconstr Surg 117:2284-91. 2006
    ..The aim of the study was to evaluate the efficacy of polyclonal immunotherapy targeted against the N-terminal of flagellin (anti-N'-fla-b) for treating severe P. aeruginosa infection in a murine burn wound model...
  23. ncbi High levels of antimicrobial coresistance among extended-spectrum-beta-lactamase-producing Enterobacteriaceae
    Mitchell J Schwaber
    Division of Epidemiology, Tel Aviv Sourasky Medical Center, 6 Weizmann St, Tel Aviv 64239, Israel
    Antimicrob Agents Chemother 49:2137-9. 2005
    ..ESBL nonproducers were more often susceptible to these agents. ESBL-producing Enterobacteriaceae represent a major source of resistance to various antibiotics...
  24. ncbi Staphylococcus aureus mediastinitis and sternal osteomyelitis following median sternotomy in a rat model
    Yoav Barnea
    Division of Epidemiology and Laboratory for Molecular Epidemiology and Antimicrobials Research, Tel Aviv Sourasky Medical Center, affiliated with the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
    J Antimicrob Chemother 62:1339-43. 2008
    ..We aimed to develop a new Staphylococcus aureus mediastinitis and sternal osteomyelitis model in rats that can be used to evaluate the efficacy of new antimicrobial treatments...
  25. ncbi Predictors of rectal carriage of carbapenem-resistant Enterobacteriaceae (CRE) among patients with known CRE carriage at their next hospital encounter
    Vered Schechner
    Division of Epidemiology, Tel Aviv Sourasky Medical Center, 6 Weizmann Street, Tel Aviv 64239, Israel
    Infect Control Hosp Epidemiol 32:497-503. 2011
    ..Very little is known about the natural history of CRE carriage. We aimed to determine the predictors of a positive CRE rectal screen test among patients with known CRE carriage screened at their next hospital encounter...
  26. ncbi CTX-M-2 and a new CTX-M-39 enzyme are the major extended-spectrum beta-lactamases in multiple Escherichia coli clones isolated in Tel Aviv, Israel
    Inna Chmelnitsky
    Division of Epidemiology and Laboratory for Molecular Epidemiology and Antibiotic Research, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Israel
    Antimicrob Agents Chemother 49:4745-50. 2005
    ..We report here a new CTX-M gene, designated bla(CTX-M-39), which revealed 99% homology with bla(CTX-M-26), with a substitution of arginine for glutamine at position 225...
  27. ncbi Efficacy of ertapenem for treatment of bloodstream infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae
    Vicki L Collins
    Division of Infectious Diseases, Wayne State University, Detroit, Michigan, USA
    Antimicrob Agents Chemother 56:2173-7. 2012
    ..From 2005 to 2010, 261 patients with ESBL BSIs were analyzed. Outcomes were equivalent between patients treated with ertapenem and those treated with group 2 carbapenems (mortality rates of 6% and 18%, respectively; P = 0.18)...
  28. ncbi Utility of the VITEK 2 Advanced Expert System for identification of extended-spectrum beta-lactamase production in Enterobacter spp
    Mitchell J Schwaber
    Division of Epidemiology, Tel Aviv Sourasky Medical Center, Israel
    J Clin Microbiol 44:241-3. 2006
    ..5%), and erroneously reported cephalosporin susceptibility in 11 isolates (28%). Refinements in the AES are required in order to improve ESBL detection in Enterobacter...
  29. ncbi Endocarditis caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae: emergence of resistance to ciprofloxacin and piperacillin-tazobactam during treatment despite initial susceptibility
    Oren Zimhony
    Division of Infectious Diseases, Kaplan Medical Center Rehovot, Hebrew University and Hadassah, Jerusalem, Israel
    Antimicrob Agents Chemother 50:3179-82. 2006
    ..We question if and how PIP-TZ susceptibility should be reported for ESBL-producing Enterobacteriaceae...
  30. ncbi Extended-spectrum beta-lactamases among Enterobacter isolates obtained in Tel Aviv, Israel
    Jacob Schlesinger
    Division of Epidemiology, Tel Aviv Sourasky Medical Center, 6 Weizmann St, Tel Aviv 64239, Israel
    Antimicrob Agents Chemother 49:1150-6. 2005
    ..The dominant ESBL identified was SHV-12...
  31. ncbi Effects of antibiotics on nosocomial epidemiology of vancomycin-resistant enterococci
    Stephan Harbarth
    Division of Infectious Diseases, Children's Hospital, Division of Infectious Diseases, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    Antimicrob Agents Chemother 46:1619-28. 2002
  32. ncbi The effects of group 1 versus group 2 carbapenems on imipenem-resistant Pseudomonas aeruginosa: an ecological study
    Yehuda Carmeli
    Division of Epidemiology, Tel Aviv Sourasky Medical Center, Tel Aviv 64239, Israel
    Diagn Microbiol Infect Dis 70:367-72. 2011
    ..0625) in multivariate analysis. Ertapenem was not associated with IMP-R PA. These data would support preferentially prescribing ertapenem rather than group 2 carbapenems where clinically appropriate...
  33. ncbi Fluoroquinolones and the risk for methicillin-resistant Staphylococcus aureus in hospitalized patients
    Stephen G Weber
    Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA
    Emerg Infect Dis 9:1415-22. 2003
    ..4; p <0.0001; ciprofloxacin OR 2.5; p = 0.005) but not MSSA. Exposure to levofloxacin or ciprofloxacin is a significant risk factor for the isolation of MRSA, but not MSSA...
  34. ncbi Surveillance cultures and duration of carriage of multidrug-resistant Acinetobacter baumannii
    Dror Marchaim
    Division of Epidemiology, Tel Aviv Sourasky Medical Center, 6 Weizmann St, Tel Aviv 64239, Israel
    J Clin Microbiol 45:1551-5. 2007
    ..The proportion of individuals with previous MDR A. baumannii isolation who remain carriers for prolonged periods is substantial. These data should be considered when designing measures to limit the spread of MDR A. baumannii...
  35. ncbi Fluoroquinolones protective against cephalosporin resistance in gram-negative nosocomial pathogens
    Mitchell J Schwaber
    Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA
    Emerg Infect Dis 10:94-9. 2004
    ....
  36. ncbi Evaluation of an accelerated protocol for detection of extended-spectrum beta-lactamase-producing gram-negative bacilli from positive blood cultures
    Shiri Navon-Venezia
    Molecular Epidemiology Laboratory, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, 6 Weizman St, Tel Aviv 64239, Israel
    J Clin Microbiol 43:439-41. 2005
    ..Results of the direct ESBL testing were reported 2.3 days sooner and were comparable to those of the standard NCCLS method with sensitivity, specificity, and positive and negative predictive values of 100, 98, 94, and 100%, respectively...
  37. ncbi Novel rat model of methicillin-resistant Staphylococcus aureus-infected silicone breast implants: a study of biofilm pathogenesis
    Ehud Arad
    Department of Plastic and Reconstructive Surgery and the Laboratory for Epidemiology and Antibiotic Research, Tel Aviv Sourasky Medical Center, Affiliated with Tel Aviv Sackler Medical School, Tel Aviv University, Tel Aviv, Israel
    Plast Reconstr Surg 131:205-14. 2013
    ..It may persist over time in the form of biofilm without overt manifestation and is extremely difficult to eradicate. The authors' aim was to establish a novel model for biofilm infection of silicone breast implants in rats...
  38. ncbi High tigecycline resistance in multidrug-resistant Acinetobacter baumannii
    Shiri Navon-Venezia
    The Laboratory for Molecular Epidemiology and Antibiotic Research, Department of Epidemiology, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
    J Antimicrob Chemother 59:772-4. 2007
    ..We aimed to evaluate the in vitro activity of tigecycline against MDR A. baumannii clones isolated before tigecycline was used in our institution...
  39. ncbi Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis
    Mitchell J Schwaber
    Division of Epidemiology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
    J Antimicrob Chemother 60:913-20. 2007
    ..We performed a systematic review and meta-analysis to examine the impact of extended-spectrum beta-lactamase (ESBL) production on mortality and delay in effective therapy in Enterobacteriaceae bacteraemia...
  40. ncbi Complete nucleotide sequence of KPC-3-encoding plasmid pKpQIL in the epidemic Klebsiella pneumoniae sequence type 258
    Azita Leavitt
    Division of Epidemiology, Molecular Epidemiology and Antibiotic Resistance Laboratory, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
    Antimicrob Agents Chemother 54:4493-6. 2010
    ..pKpQIL is a 113,637-bp, self-transmissible plasmid that belongs to the incompatibility group IncFII. It consists of a large backbone of a pKPN4-like plasmid and carries the bla(KPC-3)-containing Tn4401a transposon of a pNYC-like plasmid...
  41. ncbi Laboratory evaluation of the CHROMagar KPC medium for identification of carbapenem-nonsusceptible Enterobacteriaceae
    Jacob Moran Gilad
    Clinical Microbiology Laboratory, Tel Aviv Sourasky Medical Center, affiliated to the Sackler School of Medicine, Tel Aviv University, Tel Aviv 64239, Israel
    Diagn Microbiol Infect Dis 70:565-7. 2011
    ..coli...
  42. ncbi Accounting for the development of antibacterial resistance in the cost effectiveness of ertapenem versus piperacillin/tazobactam in the treatment of diabetic foot infections in the UK
    Jeroen P Jansen
    Mapi Values, Boston, Massachusetts 02114, USA
    Pharmacoeconomics 27:1045-56. 2009
    ....
  43. ncbi Update on Pseudomonas aeruginosa and Acinetobacter baumannii infections in the healthcare setting
    Shiri Navon-Venezia
    Divisions of Epidemiology and Infectious Diseases, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
    Curr Opin Infect Dis 18:306-13. 2005
    ..In the absence of new antibiotic agents, new modalities of treatment should be developed...
  44. ncbi Glycopeptides are no more effective than beta-lactam agents for prevention of surgical site infection after cardiac surgery: a meta-analysis
    Maureen K Bolon
    Division of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, USA
    Clin Infect Dis 38:1357-63. 2004
    ..58-1.01) and were superior for prevention of SSIs caused by methicillin-resistant gram-positive bacteria (RR, 0.54; 95% CI, 0.33-0.90). Standard prophylaxis for cardiac surgery should continue to be beta-lactams in most circumstances...
  45. ncbi The magnitude of the association between fluoroquinolone use and quinolone-resistant Escherichia coli and Klebsiella pneumoniae may be lower than previously reported
    Maureen K Bolon
    Division of Infectious Diseases, Beth Israel Deaconess Medical Center Boston, Massachusetts, USA
    Antimicrob Agents Chemother 48:1934-40. 2004
    ..5. Fluoroquinolone use is significantly associated with the isolation of fluoroquinolone-resistant Enterobacteriaceae; however, previous studies likely exaggerated the magnitude of this association...
  46. ncbi How to stem the tide of carbapenemase-producing enterobacteriaceae?: proactive versus reactive strategies
    Efraim Bilavsky
    Division of Epidemiology and Preventive Medicine, Tel Aviv Sourasky Medical Center, Israel
    Curr Opin Infect Dis 23:327-31. 2010
    ..The purpose of this review is to highlight the impact of these problematic pathogens and to examine infection control policies needed in order to limit their spread...
  47. ncbi Multidrug-resistant Acinetobacter baumannii
    Aharon Abbo
    Tel Aviv Sourasky Medical Center, 6 Weizmann Street, Tel Aviv 64239, Israel
    Emerg Infect Dis 11:22-9. 2005
    ..Penicillins were protective. The complex epidemiology may explain why the emergence of MDR A. baumannii is difficult to control...
  48. ncbi Characteristics of microorganisms cultured from infected wounds post-hysterectomy
    Anat Yerushalmy
    Department of Obstetrics and Gynecology, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
    Eur J Obstet Gynecol Reprod Biol 141:169-72. 2008
    ..To characterize organisms causing wound infection following abdominal hysterectomy...
  49. ncbi National multicenter study of predictors and outcomes of bacteremia upon hospital admission caused by Enterobacteriaceae producing extended-spectrum beta-lactamases
    Dror Marchaim
    Division of Epidemiology, Tel Aviv Sourasky Medical Center, 6 Weizmann St, Tel Aviv 64239, Israel
    Antimicrob Agents Chemother 54:5099-104. 2010
    ..Efforts should be directed to improving the detection of patients with ESBL bacteremia UHA and to providing immediate appropriate therapy...
  50. ncbi Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection
    John J Engemann
    Division of Infectious Diseases, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Clin Infect Dis 36:592-8. 2003
    ..Methicillin resistance is independently associated with increased mortality and hospital charges among patients with S. aureus SSI...
  51. ncbi Treatment options for multidrug-resistant Acinetobacter species
    Jacob Gilad
    Clinical Microbiology Laboratory, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
    Drugs 68:165-89. 2008
    ....
  52. ncbi Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact
    Valerie Aloush
    Department of Internal Medicine VI, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Israel
    Antimicrob Agents Chemother 50:43-8. 2006
    ..aeruginosa is complex. Critically ill patients that require intensive care and are treated with multiple antibiotic agents are at high risk. MDR P. aeruginosa infections are associated with severe adverse clinical outcomes...
  53. ncbi Factors associated with candidemia caused by non-albicans Candida species versus Candida albicans in the intensive care unit
    Jennifer K Chow
    Division of Geographic Medicine and Infectious Diseases, Tufts New England Medical Center, Tufts University School of Medicine, Boston, Massachusetts 02111, USA
    Clin Infect Dis 46:1206-13. 2008
    ..We examined factors associated with BSIs due to non-albicans Candida species, compared with C. albicans BSIs, in an ICU patient population...
  54. ncbi Predictors of pandemic (H1N1) 2009 virus positivity and adverse outcomes among hospitalized patients with a compatible syndrome
    Amir Shlomai
    Department of Medicine B, Tel Aviv Sourasky Medical Center, Israel
    Isr Med Assoc J 12:622-7. 2010
    ..A pandemic (H1N1) influenza A virus was identified in 2009...
  55. ncbi Treatment with a broad-spectrum cephalosporin versus piperacillin-tazobactam and the risk for isolation of broad-spectrum cephalosporin-resistant Enterobacter species
    Mitchell J Schwaber
    Department of Medicine, Beth Israel Deaconess Medical Center and Massachusetts General Hospital, Boston, Massachusetts, USA
    Antimicrob Agents Chemother 47:1882-6. 2003
    ..and the equivalence in risk associated with piperacillin-tazobactam and broad-spectrum cephalosporins may have important clinical and epidemiologic implications...
  56. ncbi Methicillin-resistant Staphylococcus aureus in neonatal intensive care unit
    Gili Regev-Yochay
    Infectious Diseases Unit, Sheba Medical Center, Tel Hashomer, Ramat Gan, 52621 Israel
    Emerg Infect Dis 11:453-6. 2005
    ..Fifteen infected neonates were identified, 2 of whom died. This outbreak illustrates how a rare community pathogen can rapidly spread through nosocomial transmission...
  57. ncbi Parental Staphylococcus aureus carriage is associated with staphylococcal carriage in young children
    Gili Regev-Yochay
    Infectious Diseases Unit, Sheba Medical Center and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
    Pediatr Infect Dis J 28:960-5. 2009
    ..Our previous study suggested that S. aureus carriage in children is associated with parental carriage. Here we wished to distinguish the different components that play a role in the risk to a child of a S. aureus-carrying parent...
  58. ncbi Epidemiological interpretation of studies examining the effect of antibiotic usage on resistance
    Vered Schechner
    Division of Epidemiology and Preventive Medicine, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
    Clin Microbiol Rev 26:289-307. 2013
    ..Approaches to measuring antibiotic use and antibiotic resistance are presented. Important methodological issues such as confounding, establishing temporality, and control group selection are examined...
  59. ncbi Hospital-acquired infective endocarditis: should the definition be broadened?
    Ronen Ben-Ami
    Infectious Diseases Unit, Tel Aviv Sourasky Medical Center, Sackler School of Medicine, Tel Aviv University, Israel
    Clin Infect Dis 38:843-50. 2004
    ..We conclude that characteristics of hospital-acquired IE extend to episodes arising within 6 months after discharge from the hospital and suggest that the definition of hospital-acquired IE be broadened to include these episodes...
  60. ncbi Epidemiological interpretation of antibiotic resistance studies - what are we missing?
    Mitchell J Schwaber
    Division of Epidemiology, Tel Aviv Sourasky Medical Center, Tel Aviv 64239, Israel
    Nat Rev Microbiol 2:979-83. 2004
    ..A more appropriate measure of this burden is the rate of isolation of resistant organisms, that is, the absolute number of resistant isolates in a population over time...
  61. ncbi Mupirocin prophylaxis to prevent Staphylococcus aureus infection in patients undergoing dialysis: a meta-analysis
    Evelina Tacconelli
    Division of Infectious Diseases, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215, USA
    Clin Infect Dis 37:1629-38. 2003
    ..Mupirocin prophylaxis substantially reduces the rate of S. aureus infection in the dialysis population. Optimal regimens that minimize the emergence of mupirocin resistance need to be explored...
  62. ncbi Antimicrobial resistance and patient outcomes: the hazards of adjustment
    Mitchell J Schwaber
    Division of Epidemiology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
    Crit Care 10:164. 2006
    ..We discuss how failure to distinguish between confounders and intermediate variables can bias the analysis, and we address methods of approaching this issue...
  63. ncbi The establishment of a Pseudomonas aeruginosa-infected burn-wound sepsis model and the effect of imipenem treatment
    Yoav Barnea
    Department of Plastic and Reconstructive Surgery, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
    Ann Plast Surg 56:674-9. 2006
    ..We present a standardized Pseudomonas aeruginosa (PA) infected burn-wound model in mice for evaluating new antimicrobials and therapy strategies for PA infections and demonstrate the effect of the antibiotic imipenem in this model...
  64. ncbi Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis
    Sara E Cosgrove
    Division of Infectious Diseases, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, Massachusetts, USA
    Clin Infect Dis 36:53-9. 2003
    ..54-2.42; P<.001); significant heterogeneity was present. We explored the reasons for heterogeneity by means of subgroup analyses. MRSA bacteremia is associated with significantly higher mortality rate than is MSSA bacteremia...
  65. ncbi Antibacterial properties of dermaseptin S4 derivatives with in vivo activity
    Shiri Navon-Venezia
    Division of Infectious Diseases, Sourasky Medical Center, Tel Aviv, Israel
    Antimicrob Agents Chemother 46:689-94. 2002
    ..Overall, the data suggest that dermaseptin S4 derivatives could be useful in treatment of infections, including infections caused by multidrug-resistant bacteria...
  66. ncbi Studies of bloodstream infection outcomes: reading between the lines
    Sara E Cosgrove
    Infect Control Hosp Epidemiol 24:884-6. 2003
  67. ncbi The economic effect of oral linezolid versus intravenous vancomycin in the outpatient setting: the payer perspective
    Peggy S McKinnon
    Clinical Research Infectious Diseases, Barnes Jewish Hospital, St Louis, Missouri 63110, USA
    Manag Care Interface 20:23-34. 2007
    ..Outpatient treatment with oral linezolid was associated with significantly lower resource utilization and total medical costs compared with IV vancomycin...
  68. ncbi Occurrence and phenotypic characteristics of extended-spectrum beta-lactamases among members of the family Enterobacteriaceae at the Tel-Aviv Medical Center (Israel) and evaluation of diagnostic tests
    Shiri Navon-Venezia
    Laboratory for Molecular Epidemiology, Tel-Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
    J Clin Microbiol 41:155-8. 2003
    ..The CTX-CLAV combination confirmed ESBL producers better than the CTZ-CLAV combination, with sensitivity varying between species. Combined CTZ-CLAV and CTX-CLAV testing detected all these strains; CPD-CLAV provided no additional benefit...
  69. ncbi Reference group choice and antibiotic resistance outcomes
    Keith S Kaye
    Duke University Medical Center, Durham, North Carolina 27710, USA
    Emerg Infect Dis 10:1125-8. 2004
    ..Cases were compared to uninfected patients and patients infected with the corresponding, susceptible organism. VRE and MRSA were associated with adverse outcomes. The effect was greater when uninfected control patients were used...
  70. ncbi First national surveillance of susceptibility of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. to antimicrobials in Israel
    Raul Colodner
    Clinical Microbiology Laboratory, Ha Emek Medical Center, 18101, Afula, Israel
    Diagn Microbiol Infect Dis 57:201-5. 2007
    ..3% (12.3-28.5%, 96/256). Coresistance, cross-resistance, and variability between institutions were high. Only carbapenems retain predicted activity against ESBL-producing E. coli and Klebsiella spp. across Israeli hospitals...
  71. ncbi Enterococcal bacteraemia: epidemiological, microbiological, clinical and prognostic characteristics, and the impact of high level gentamicin resistance
    Hila Shaked
    Infectious Diseases Unit, Tel-Aviv Sourasky Medical Centre, Tel-Aviv, Israel
    Scand J Infect Dis 38:995-1000. 2006
    ..6, p<0.00001) and HLGR (OR=6.4, p=0.006). It was concluded that HLGR adversely affects the outcome of bacteraemic enterococcal infection...
  72. ncbi Should third-generation cephalosporins be avoided against AmpC-inducible Enterobacteriaceae?
    David M Livermore
    Clin Microbiol Infect 10:84-5. 2004
  73. ncbi Prior antimicrobial therapy and risk for hospital-acquired Candida glabrata and Candida krusei fungemia: a case-case-control study
    Michael Y Lin
    University of Chicago Hospitals, Illinois, USA
    Antimicrob Agents Chemother 49:4555-60. 2005
    ..glabrata or C. krusei candidemia. Further studies are needed to prospectively analyze specific antimicrobial risks for nosocomial candidemia across multiple hospital centers...
  74. ncbi Association between carriage of Streptococcus pneumoniae and Staphylococcus aureus in Children
    Gili Regev-Yochay
    Sheba Medical Center, Tel Hashomer, Israel
    JAMA 292:716-20. 2004
    ..Of particular significance may be an interaction between Streptococcus pneumoniae and Staphylococcus aureus, in view of the recent emergence of community-acquired methicillin-resistant S aureus...
  75. ncbi Effect of various antibacterial preparations on the pathogenic oral flora in elderly patients fed via nasogastric tube
    Arthur Leibovitz
    Shmuel-Harofeh Hospital, Geriatric Medical Center, POB 2, Be'er-Ya'akov, 70350, Israel
    Antimicrob Agents Chemother 49:3566-8. 2005
    ..We prospectively evaluated six antiseptic compounds in nasogastric tube-fed frail elderly patients; only polymixine reduced oropharyngeal colonization with GNB. None had an effect on S. aureus colonization...
  76. ncbi Control-group selection importance in studies of antimicrobial resistance: examples applied to Pseudomonas aeruginosa, Enterococci, and Escherichia coli
    Anthony D Harris
    Department of Epidemiology and Preventive Medicine, University of Maryland School of Medicine, and VA Maryland Health Care System, Baltimore, MD, USA
    Clin Infect Dis 34:1558-63. 2002
    ..68). The selection of control patients from the potentially suboptimal control type 1 can falsely identify certain antibiotics and overestimate the OR of the resistance-defining antibiotic...
  77. ncbi Differential effects of levofloxacin and ciprofloxacin on the risk for isolation of quinolone-resistant Pseudomonas aeruginosa
    Keith S Kaye
    Duke University Medical Center, Durham, NC 27710, USA
    Antimicrob Agents Chemother 50:2192-6. 2006
    ..6; 95% CI = 0.4 to 0.9), whereas ciprofloxacin had no significant effect (OR = 1.0; 95% CI = 0.6 to 1.8). In conclusion, the use of levofloxacin, but not ciprofloxacin, was associated with isolation of QR P. aeruginosa...
  78. ncbi Health and economic outcomes of the emergence of third-generation cephalosporin resistance in Enterobacter species
    Sara E Cosgrove
    Department of Medicine, The John Hopkins Hospital, 1830 E Monument St, Room 9020, Baltimore, MD 21287, USA
    Arch Intern Med 162:185-90. 2002
    ..This study evaluated the clinical and economic impact of the emergence of third-generation cephalosporin-resistant Enterobacter species...
  79. ncbi Clinical and economic impact of common multidrug-resistant gram-negative bacilli
    Christian G Giske
    Clinical Microbiology L2:02, Karolinska Institutet-MTC, Karolinska University Hospital Solna, Stockholm SE-17176, Sweden
    Antimicrob Agents Chemother 52:813-21. 2008
  80. ncbi Predictors of mortality in patients with bloodstream infection due to ceftazidime-resistant Klebsiella pneumoniae
    Deverick J Anderson
    Duke University Medical Center, Division of Infectious Disease, DUMC Box 3824, Durham, NC 27710, USA
    Antimicrob Agents Chemother 50:1715-20. 2006
    ..32; 95% confidence interval, 1.07 to 10.3). Thus, among patients with BSI due to CAZ-R K. pneumoniae, a delay in the initiation of effective therapy of greater than 72 h after BSI was associated with a >3-fold increase in mortality risk...
  81. ncbi Genotypic and phenotypic analysis of Clostridium difficile correlated with previous antibiotic exposure
    Matthew H Samore
    VA Salt Lake City Health Care System, and Division of Clinical Epidemiology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT 84132, USA
    Microb Drug Resist 12:23-8. 2006
    ..Resistance of specific C. difficile strains to clindamycin and other antimicrobial agents may contribute to their hospital dissemination and explain, in part, the propensity of clindamycin to trigger nosocomial outbreaks...
  82. ncbi Mechanisms by which antibiotics promote dissemination of resistant pneumococci in human populations
    Matthew H Samore
    Division of Clinical Epidemiology, Department of Internal Medicine, School of Medicine, University of Utah, Salt Lake City, UT 84132, USA
    Am J Epidemiol 163:160-70. 2006
    ..Penicillins accelerate clearance of susceptible strains. The effect of penicillins in increasing resistance is shared equally by treated and untreated members of the population...
  83. ncbi Infection of a ventriculoatrial shunt with phenotypically variable Staphylococcus epidermidis masquerading as polymicrobial bacteremia due to various coagulase-negative Staphylococci and Kocuria varians
    Ronen Ben-Ami
    Infectious Diseases Unit, Tel-Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
    J Clin Microbiol 41:2444-7. 2003
    ..epidermidis may affect identification to the species level by phenotype-based identification systems. Caution should be exercised when differentiating between true infection and contamination based on strain identification...
  84. ncbi The case-case-control study design: addressing the limitations of risk factor studies for antimicrobial resistance
    Keith S Kaye
    Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA
    Infect Control Hosp Epidemiol 26:346-51. 2005
    ..There are significant limitations of the standard case-control study design for identifying risk factors for resistant organisms. The objective of this study was to develop a study design to overcome these limitations...
  85. ncbi The impact of antimicrobial resistance on health and economic outcomes
    Sara E Cosgrove
    Division of Infectious Disease, Johns Hopkins Hospital, Baltimore, MD, USA
    Clin Infect Dis 36:1433-7. 2003
    ....
  86. ncbi Impact of severity of illness bias and control group misclassification bias in case-control studies of antimicrobial-resistant organisms
    Anthony D Harris
    Department of Epidemiology and Preventive Medicine, University of Maryland, College Park, USA
    Infect Control Hosp Epidemiol 26:342-5. 2005
    ..If this bias exists, these studies might be expected to report lower odds ratios (ORs) because control-patients would be more like case-patients...
  87. ncbi Raising standards while watching the bottom line: making a business case for infection control
    Eli N Perencevich
    Department of Epidemiology and Preventive Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    Infect Control Hosp Epidemiol 28:1121-33. 2007
    ....
  88. ncbi Antibiotic therapy in the demented elderly population: redefining the ethical dilemma
    Mitchell J Schwaber
    Arch Intern Med 168:349-50. 2008